Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 10:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 977 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Open-label Standard of Care Clear all
Completed Phase 1Phase 2 Interventional

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

NCT01260506
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
VB-111, Bevacizumab
Drug
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 12, 2026, 10:49 AM EDT
Completed Phase 2 Interventional Results available

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

NCT03739710
View directory record Official record
Conditions
Neoplasms
Interventions
Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, Dostarlimab, GSK6097608
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
7
States / cities
Los Angeles, California • St Louis, Missouri • The Bronx, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Sep 12, 2026, 10:49 AM EDT
Active, not recruiting Phase 1 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions
Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 12, 2026, 10:49 AM EDT
Recruiting Phase 2 Interventional

BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)

NCT06773910
View directory record Official record
Conditions
Limited Stage Small Cell Lung Cancer
Interventions
BMS-986489, Durvalumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
34
States / cities
Daphne, Alabama • Santa Barbara, California • Fort Myers, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 12, 2026, 10:49 AM EDT
Completed Phase 3 Interventional Results available

A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

NCT03777176
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
Dasiglucagon, Standard of Care
Drug · Other
Lead sponsor
Zealand Pharma
Industry
Eligibility
3 Months to 12 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 12, 2026, 10:49 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

NCT04452214
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Urothelial Carcinoma, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma
Interventions
CAN04, Pembrolizumab, Carboplatin, Pemetrexed
Drug
Lead sponsor
Cantargia AB
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Aurora, Colorado • Lake Mary, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Sep 12, 2026, 10:49 AM EDT
Not listed Not applicable Interventional

Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) Also Known as TriAlign™.

NCT02574650
View directory record Official record
Conditions
Chronic Symptomatic Functional Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Heart Valve Disease
Interventions
Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)
Device
Lead sponsor
Mitralign, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Sep 12, 2026, 10:49 AM EDT
Suspended Phase 1Phase 2 Interventional

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

NCT05101356
View directory record Official record
Conditions
Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm, Metastatic Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Adenocarcinoma, Recurrent Malignant Solid Neoplasm
Interventions
Antineoplastic Vaccine, Sargramostim, Pembrolizumab
Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 12, 2026, 10:49 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

NCT02082522
View directory record Official record
Conditions
Hilar Cholangiocarcinoma
Interventions
Photodynamic therapy-Photofrin, Stenting procedure, Chemotherapy regimen
Drug · Procedure
Lead sponsor
Concordia Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 12, 2026, 10:49 AM EDT
Terminated Phase 2 Interventional Results available

A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD

NCT00457951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Open-Label, Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride, ODSH
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Orange, California • Marietta, Georgia • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Sep 12, 2026, 10:49 AM EDT
Recruiting Phase 4 Interventional

Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing

NCT07326553
View directory record Official record
Conditions
Diabete Mellitus, Foot Ulcer Chronic
Interventions
Placental Membrane
Biological
Lead sponsor
BioXTek
Industry
Eligibility
45 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 12, 2026, 10:49 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures

NCT04519645
View directory record Official record
Conditions
Electroencephalographic Neonatal Seizures, Epilepsy
Interventions
Lacosamide intravenous, Lacosamide oral, Active Comparator
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
Up to 28 Days
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
La Jolla, California • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 12, 2026, 10:49 AM EDT
Withdrawn Phase 3 Interventional

Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 Infection

NCT04675086
View directory record Official record
Conditions
Covid19, Pneumonia, Viral
Interventions
alpha1-proteinase inhibitor, Antiviral Agents
Drug
Lead sponsor
Blessing Corporate Services, Inc
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Hannibal, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Sep 12, 2026, 10:49 AM EDT
Completed Phase 2 Interventional

Personalized Antiplatelet Secondary Stroke PRevenTion

NCT03979781
View directory record Official record
Conditions
Ischemic Stroke, TIA
Interventions
tailored antiplatelet selection, standard of care
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 12, 2026, 10:49 AM EDT
Completed Phase 1Phase 2 Interventional

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

NCT03699319
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
CPI 613, Oxaliplatin, Irinotecan, 5-flurouracil, Folinic acid
Drug
Lead sponsor
David Bajor, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 12, 2026, 10:49 AM EDT
Completed Phase 3 Interventional Results available

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

NCT02973789
View directory record Official record
Conditions
Nonsmall Cell Lung Cancer, NSCLC
Interventions
NovoTTF-200T, Immune checkpoint inhibitors or docetaxel
Device · Drug
Lead sponsor
NovoCure GmbH
Industry
Eligibility
22 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
73
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 12, 2026, 10:49 AM EDT
Completed Phase 2 Interventional Results available

Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients

NCT00658359
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Cyclosporine, CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
37
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Sep 12, 2026, 10:49 AM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene

NCT05497453
View directory record Official record
Conditions
Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Hepatocellular Cancer, Liver Cancer, Liver, Cancer Of, Non-Resectable
Interventions
OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two, Checkpoint Inhibitor, Immune
Drug
Lead sponsor
Omega Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Duarte, California • Gainesville, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 12, 2026, 10:49 AM EDT
Recruiting Phase 2 Interventional

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

NCT07489066
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC), Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Disease, Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous
Interventions
PF-08634404, Chemotherapy Regimen 1, Chemotherapy Regimen 2
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
Huntsville, Alabama • Athens, Georgia • Hinsdale, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 12, 2026, 10:49 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

NCT02130557
View directory record Official record
Conditions
Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive
Interventions
Bosutinib, Imatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
65
States / cities
Anaheim, California • Atlanta, Georgia • Honolulu, Hawaii + 40 more
Source: ClinicalTrials.gov public record
Updated May 17, 2021 · Synced Sep 12, 2026, 10:49 AM EDT
Completed Phase 1 Interventional Results available

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

NCT02327169
View directory record Official record
Conditions
Advanced Nonhematologic Malignancies
Interventions
MLN2480, MLN0128, Alisertib, Paclitaxel, Cetuximab, Irinotecan
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 12, 2026, 10:49 AM EDT
Terminated Not applicable Interventional Results available

Clinical Trial to Evaluate Blister Graft Utilizing a Novel Harvesting Device for Treatment of Venous Leg Ulcers

NCT02148302
View directory record Official record
Conditions
Impaired Wound Healing, Venous Insufficiency of Leg, Diabetic Ulcers
Interventions
Harvesting Device (CelluTome©)
Device
Lead sponsor
SerenaGroup, Inc.
Network
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Boca Raton, Florida • Homestead, Florida • Largo, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Sep 12, 2026, 10:49 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

NCT04688931
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions
UGN-102, TURBT
Drug · Procedure
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
33
States / cities
Tucson, Arizona • Loma Linda, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Sep 12, 2026, 10:49 AM EDT
Recruiting Phase 3 Interventional

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

NCT06699212
View directory record Official record
Conditions
Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin, Cisplatin, 5-fluorouracil, Paclitaxel, Docetaxel
Combination Product · Biological · Drug
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Duarte, California • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 12, 2026, 10:49 AM EDT